The recent health emergency faced in the last two years was caused by the rapid spread of a virus belonging to the Coronaviridae family: SARS-CoV-2. It is a Betacoronavirus which can cause severe acute respiratory syndrome (CoViD19). In June 2022 there are more of 500 million cases and more than 6 million deaths worldwide. Other two epidemics belonging to the same genus of Coronavirus have claimed numerous lives, in 2002 (SARS-CoV-1) and in 2012 (MERS-CoV). Furthermore an aspect that should not be underestimated is that the deaths from CoViD19 were also caused by infections secondary occurring following SARS-CoV-2 infection. At present, studies are being conducted for the future use of bacteriophages in the treatment of patients affected by CoViD19, in the development of new vaccines and antibodies and in the stimulation of host's immune system to elicit a faster and more effective response. Bacteriophages are viruses that infect bacteria, very common in nature, inexpensive for molecular manipulations and ductile in use. The use of phages in the fight against infectious agents e systemic diseases (tumors and autoimmune diseases) started experimentally in the 90s could offer today an opportunity not to be underestimated in the diagnosis and treatment of CoViD19. Therefore their use could offer new approaches to address the future challenges facing the world of the microorganisms it will bring to man.
La recente emergenza sanitaria affrontata negli ultimi anni è stata causata dalla rapida diffusione di un virus appartenente alla famiglia dei Coronaviridae: SARS-CoV-2. Si tratta di un Betacoronavirus che può provocare una sindrome respiratoria acuta grave (CoViD19). A giugno 2022 si registrano più di 500 milioni di casi e più di 6 milioni di decessi in tutto il mondo. In realtà non è l’unico virus appartenente allo stesso genere (Coronavirus) ad essersi diffuso in pochissimo tempo: altre due epidemie hanno provocato numerose vittime, nel 2002 (SARS-CoV-1) e nel 2012 (MERS-CoV). Inoltre, un aspetto da non sottovalutare è che i decessi per CoViD19 sono stati causati anche da infezioni secondarie sopraggiunte in seguito all’infezione da SARS-CoV-2. Al momento, si stanno conducendo studi per un futuro utilizzo di batteriofagi nel trattamento di pazienti affetti da CoViD19, nello sviluppo di nuovi vaccini e anticorpi e nella stimolazione del sistema immunitario dell’ospite per suscitare una risposta più rapida ed efficace. I batteriofagi sono virus che infettano i batteri, molto diffusi in natura, poco costosi per le manipolazioni molecolari e duttili nell’utilizzo. L’uso di fagi nella lotta contro agenti infettivi e malattie sistemiche (tumori e malattie autoimmuni) iniziato sperimentalmente negli anni ’90 potrebbe offrire oggi un’opportunità da non sottovalutare nella diagnosi e trattamento del CoViD19. Pertanto, il loro utilizzo potrebbe offrire nuovi approcci per affrontare le future sfide che il mondo dei microrganismi apporterà all’uomo.
Studi clinici e sperimentali sul possibile utilizzo dei batteriofagi nella lotta contro il SARS-CoV-2
POLIDORO, MARIANGELA
2021/2022
Abstract
The recent health emergency faced in the last two years was caused by the rapid spread of a virus belonging to the Coronaviridae family: SARS-CoV-2. It is a Betacoronavirus which can cause severe acute respiratory syndrome (CoViD19). In June 2022 there are more of 500 million cases and more than 6 million deaths worldwide. Other two epidemics belonging to the same genus of Coronavirus have claimed numerous lives, in 2002 (SARS-CoV-1) and in 2012 (MERS-CoV). Furthermore an aspect that should not be underestimated is that the deaths from CoViD19 were also caused by infections secondary occurring following SARS-CoV-2 infection. At present, studies are being conducted for the future use of bacteriophages in the treatment of patients affected by CoViD19, in the development of new vaccines and antibodies and in the stimulation of host's immune system to elicit a faster and more effective response. Bacteriophages are viruses that infect bacteria, very common in nature, inexpensive for molecular manipulations and ductile in use. The use of phages in the fight against infectious agents e systemic diseases (tumors and autoimmune diseases) started experimentally in the 90s could offer today an opportunity not to be underestimated in the diagnosis and treatment of CoViD19. Therefore their use could offer new approaches to address the future challenges facing the world of the microorganisms it will bring to man.File | Dimensione | Formato | |
---|---|---|---|
TESI__POLIDORO_MARIANGELA.pdf
accesso aperto
Dimensione
1.14 MB
Formato
Adobe PDF
|
1.14 MB | Adobe PDF | Visualizza/Apri |
I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/20.500.12075/9660